Smith+Nephew Advances Knee Replacement With LANDMARK System
London, United Kingdom, September 22, 2026 Smith+Nephew has announced U.S. FDA 510(k) clearance for its LANDMARK⢠Total Knee System...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
London, United Kingdom, September 22, 2026 Smith+Nephew has announced U.S. FDA 510(k) clearance for its LANDMARK⢠Total Knee System...
Vancouver, British Columbia, Canada, September 21, 2026 Smith+Nephew, a global medical technology company, is showcasing a broad portfolio of...
London, UK, August 17, 2026 Smith+Nephew, a global medical technology company, has announced the launch of its new FLOW...
LONDON, United Kingdom, July 29, 2026 Smith+Nephew has achieved a significant regulatory milestone after receiving U.S. Food and Drug...
LONDON, United Kingdom, June 8, 2026 Smith+Nephew has announced the successful completion of the first clinical procedures using its...
BREMEN, Germany, May 5, 2026 Smith+Nephew, the global medical technology company specializing in advanced wound management and surgical innovation,...
